Group 1 - The company expects a net profit of 100 million to 130 million yuan for the current reporting period, a decrease of 39.95% to 53.81% compared to the same period last year, where the net profit was 216.48 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is estimated to be between 91 million and 121 million yuan, reflecting a decline of 40.50% to 55.25% from the previous year's 203.37 million yuan [1] - The primary reason for the decline in performance is attributed to significant price reductions in the company's main products due to the nationwide implementation of centralized procurement, leading to decreased revenue and profit margins [1] Group 2 - The impact of non-recurring gains and losses on net profit is estimated to be around 9 million yuan, mainly from government subsidies received [1]

Core Viewpoint - The company Fu'an Pharmaceutical (300194) expects a significant decline in net profit for the first half of 2025, primarily due to price reductions in its main products as a result of nationwide centralized procurement [1] Financial Performance - The projected net profit attributable to shareholders for the period from January 1, 2025, to June 30, 2025, is estimated to be between 100 million to 130 million yuan, representing a year-on-year decrease of 39.95% to 53.81% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 91 million to 121 million yuan, reflecting a year-on-year decline of 40.50% to 55.25% [1] Market Conditions - The decline in performance is primarily attributed to the implementation of centralized procurement across the country, which has led to a substantial decrease in the sales prices of the company's main products [1]